Literature DB >> 10906154

Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma.

Andreas Pansky1, Andreas DE Weerth2, Elizaveta Fasler-Kan1, Jean-Louis Boulay1, Martina Schulz2, Sylvia Ketterer1, Cristin Selck2, Christoph Beglinger1, Tammo VON Schrenck2, Pius Hildebrand1.   

Abstract

Bombesin-like peptides typically act as neurotransmitters along the brain-gut axis and as growth factors in various human tissues. The present study demonstrates the expression of gastrin releasing peptide (GRP)-preferring bombesin receptors in human renal cell carcinoma but not in normal kidney tissue. The expression of GRP receptors was characterized at the mRNA level by reverse transcription-PCR, as well as at the protein level by binding of (125)I-[Tyr(4)] bombesin to membranes prepared from tumor tissue (K(d) 0.3 nM) and healthy kidney tissue from the same four patients. GRP receptors were also demonstrated in four human kidney carcinoma cell lines (A-498, CAKI-1, CAKI-2, and ACHN). The effects of bombesin/GRP agonists and/or antagonists on growth were investigated in vitro on CAKI-2 cells, which expressed large amounts of GRP receptors. Cell numbers stimulated by 10% fetal calf serum were significantly stimulated by interleukin-1beta (control) and GRP-7 (10(-7) M), both in the range of 136 to 148%; addition of the GRP receptor antagonist acetyl-GRP(20-27) (10(-6) M) completely reversed this effect. Bombesin alone (10(-6) M) significantly stimulated CAKI-2 cells (129%) cultured with 0.5% fetal calf serum, whereas another antagonist, D-Phe6,Leu13,(CH2NH)Leu14 bombesin(6-14) (1 microM), alone did not inhibit growth, thus excluding an autocrine mechanism. These results indicate for the first time that malignant transformation of human kidney tissue into renal cell carcinoma is accompanied by novel expression of GRP receptors. Bombesin-like peptides might act as mitogens in these carcinomas, and they might be useful as diagnostic or therapeutic tools such as tumor imaging or internal radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906154     DOI: 10.1681/ASN.V1181409

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

Review 1.  Paraneoplastic endocrine syndromes: a review.

Authors:  Ronald A DeLellis; Ling Xia
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 2.  Targeting GRPR in urological cancers--from basic research to clinical application.

Authors:  Rosalba Mansi; Achim Fleischmann; Helmut R Mäcke; Jean C Reubi
Journal:  Nat Rev Urol       Date:  2013-03-19       Impact factor: 14.432

3.  In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.

Authors:  Regi Thomas; Jianqing Chen; Martine M Roudier; Robert L Vessella; Laura E Lantry; Adrian D Nunn
Journal:  Clin Exp Metastasis       Date:  2008-10-31       Impact factor: 5.150

4.  Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Authors:  M Fani; H R Maecke; S M Okarvi
Journal:  Theranostics       Date:  2012-05-16       Impact factor: 11.556

5.  Independent prognostic genes and mechanism investigation for colon cancer.

Authors:  Chunsheng Li; Zhen Shen; Yangyang Zhou; Wei Yu
Journal:  Biol Res       Date:  2018-04-13       Impact factor: 5.612

6.  Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer.

Authors:  Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova
Journal:  Pharmaceutics       Date:  2021-01-30       Impact factor: 6.321

7.  Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.

Authors:  Yan Li; Yiyi Li; Zijin Xia; Dun Zhang; Xiaomei Chen; Xinyu Wang; Jing Liao; Wei Yi; Jun Chen
Journal:  Aging (Albany NY)       Date:  2021-12-13       Impact factor: 5.682

8.  Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells.

Authors:  Jens Bedke; Bernhard Hemmerlein; Christina Perske; Andreas Gross; Markus Heuser
Journal:  World J Urol       Date:  2009-12-13       Impact factor: 4.226

Review 9.  Radiolabeled antibodies in renal cell carcinoma.

Authors:  Alexander B Stillebroer; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders; Otto C Boerman
Journal:  Cancer Imaging       Date:  2007-11-19       Impact factor: 3.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.